Please login to the form below

Not currently logged in
Email:
Password:

DBV refiles peanut allergy immunotherapy in the US

Follows initial manufacturing concerns

dbv

DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. Now, it’s having a second attempt.

The French biotech has submitted a new dossier to the FDA seeking approval for the product as a treatment for peanut-allergic children aged four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review.

Both candidates have breakthrough status, meaning that they will be granted speedy reviews and, unless there is another mishap, Aimmune should now get its AR101 therapy to the US market first with a label covering the four to 17 age range.

Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee meeting to discuss the drug in September. The US company also seems to be in the lead in Europe, with a filing there due in the next few months.

Viaskin Peanut is a patch worn on the skin that delivers peanut allergens in a controlled manner to stimulate immune tolerance, while Aimmune’s drug is given orally. The two are being held up as potential life-saving therapies for the estimated six million people with this allergy in the US and Europe alone.

The withdrawal of the marketing application came after the FDA expressed concerns about manufacturing. DBV says its new filing “incorporates additional data needs on manufacturing procedures and quality controls” requested by the agency.

GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug claiming around a third and other players such as Prota Therapeutics and Camallergy playing minor roles. Meanwhile, Clarivate Analytics thinks AR1010 will makes sales of almost $1.2bn at its peak.

“This is an important milestone for DBV, as we are one step closer towards potentially bringing Viaskin Peanut to patients,” said the company chief executive Daniel Tassé.

”Everyone at DBV is highly committed to potentially addressing the significant unmet medical need facing peanut-allergic patients,” he added.

Article by
Phil Taylor

8th August 2019

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....